Anixa Biosciences to Present at the 2026 Cantor Fitzgerald Global Healthcare Conference Highlighting its Breast Cancer Vaccine and Ovarian Cancer CAR-T Therapy
Anixa Biosciences announced it will present at the Cantor Fitzgerald Global Healthcare Conference, highlighting progress in its oncology pipeline developed with Cleveland Clinic and Moffitt Cancer Center. The company's breast cancer vaccine met all primary endpoints in a Phase 1 trial with a 74% immune response rate, and preparations for a Phase 2 trial are now underway.
Key figures
- Drug Name
- Breast cancer vaccine, lira-cel
- Phase Of Trial
- Phase 1
- Cohort level
- 5
- Immune response rate
- 74%
- Longest survival months
- 28
- Survival patients over 1yr
- 4
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.